Piramal Pharma Ltd
NSE: PPLPHARMA BSE: 543635
₹237.76
+4.07 (1.74%)
Sat, 07 Nov 2026, 06:46 pm
Market Cap (in Cr)31133.58
PE Ratio0
Dividend0.06
Health Technology
Pharmaceuticals: Major
24.5KPiramal Pharma Ltd Company History
2020
- The company was incorporated on March 4, 2020 at Mumbai as a public limited company.
- The company acquired the pharmaceutical business from PEL.
- The company received a 20% Strategic Growth Investment by Carlyle.
- The company increased its stake to 100% in CCPL.
- Piramal Pharma and Navin Fluorine mutually agreed on Piramal increasing its stake to 100% in Convergence Chemicals.
- Piramal Pharma Solutions collaborated with Epirium Bio on an exclusive integrated development and manufacturing program for orphan drugs.
- Piramal Pharma Solutions announced an integrated development program with Bolt Biotherapeutics for immune-stimulating antibody conjugates and sterile fill-finish.
- Piramal Critical Care announced a strategic partnership with US-based pharmaceutical outsourcing facility Medivant Healthcare.
2021
- The company acquired HPPL.
- Piramal Pharma Solutions announced the winner of its Inaugural Award for Excellence in Patient Centricity.
- Piramal Pharma Solutions entered into a Master Services Agreement with Plus Therapeutics, Inc.
- Piramal Pharma Limited's Consumer Products Division launched 'i-feel'.
2022
- The company acquired a minority stake in Yapan Bio Private Limited.
- The Composite Scheme of Arrangement was sanctioned by the NCLT on August 12, 2022.
- Piramal Pharma Solutions announced the winner of its September 2022 Award for Excellence in Patient Centricity.
- Piramal Pharma Solutions launched ADCelerate, a rapid, integrated approach to taking ADCs to IND.
- Piramal Pharma Solutions held the grand opening ceremony for its new API plant at Aurora, Canada manufacturing site.
- Piramal Pharma Solutions' new API plant in Canada went online and initial production runs were successfully completed.
2023
- The company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.
